New leukemia treatment enters first human safety tests
NCT ID NCT06709131
Summary
This is an early-stage study to check the safety and find the right dose of an experimental treatment called CT0991 for adults with acute myeloid leukemia that has returned or not responded to other therapies. It will involve up to 24 participants. The main goal is to see what side effects occur and determine a safe dose range before testing how well it might work.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA(AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The first affiliated hospital of medical college of zhejiang university
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.